NVUS News and Press, Novus Therapeutics Inc. From 06/01/20

Gainers: Cemtrex (NASDAQ: CETX )  +209% . More news on: Cemtrex, Inc., Digital Ally, Inc., Allied Esports Entertainment Inc., Stocks on the move, , Read more ...

Nano cap Novus Therapeutics ( NVUS -47.2% ) craters on a 13x surge in volume in reaction to unsuccessful results from a Phase 2a clinical trial evaluating intranasal OP0201 as an adjunct to antibiotic therapy in patients with acute otitis media (eye infection). More news on: Novus Th...

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...

Resolution of middle ear effusion in 56% of OP0201 vs. 38% of placebo patients (p=0.07) Company engages financial advisors to explore strategic options Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with...

Novus Therapeutics (NASDAQ: NVUS ): Q1 GAAP EPS of -$0.47 misses by $0.31 . More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020. Operational Highlights Raised gross proceeds...

Novus Therapeutics (NASDAQ: NVUS ): Q4 GAAP EPS of -$0.32 misses by $0.06 . More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Data from the fully enrolled phase 2a efficacy study in infants and children with acute otitis media to be announced by early June 2020 Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, n...

– Phase 2a study C-006 enrollment to be completed in 1Q 2020; data expected in 2Q 2020 – Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate ...